Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole

Chiyo Imamura, Kenichi Furihata, Shinichiro Okamoto, Yusuke Tanigawara

研究成果: Article

17 引用 (Scopus)

抜粋

This study evaluated the effects of cytochrome P450 (CYP) 2C19 polymorphisms on tacrolimus pharmacokinetics when coadministered with voriconazole. Eighteen healthy volunteers, including 6 individuals in each CYP2C19 genotype (extensive metabolizers [EMs], intermediate metabolizers [IMs], and poor metabolizers [PMs]), received a single oral dose of 3 mg tacrolimus alone or in combination with 200 mg voriconazole twice daily at steady state. When tacrolimus was coadministered with voriconazole, a significant increase in area under its concentration-time curve (AUC0-24) was observed for all genotypes. AUC0-12 of voriconazole in IMs and PMs were significantly higher than that in EMs (P 0-24 of tacrolimus in combination with voriconazole in IMs and PMs were also significantly higher than that in EMs (P

元の言語English
ページ(範囲)408-413
ページ数6
ジャーナルJournal of Clinical Pharmacology
56
発行部数4
DOI
出版物ステータスPublished - 2016 4 1

    フィンガープリント

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

これを引用